This article only represents the author's own views.
One of China’s leading makers of novel drugs, BeiGene Ltd. (688235.SH; 6160.HK; BGNE.US), has arrived at a landmark on its earnings journey: its first quarterly profit.
That is, according to one widely accepted accounting measure. By another, it still has a few steps further to go. Investors have been eagerly tracking the company’s progress towards the breakeven point, hoping that growing demand for BeiGene’s blood cancer drugs would finally push its results definitively from the red into the black.
您已閱讀11%（555字），剩余89%（4585字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。